1418 Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan

Jacob Zaemes,Shaked Lev Ari,Lauren Pascual,Opeyemi A Jegede,Natali Arias-Orozco,Brittany Sinclaire,Alexandra Dellapia,Rachel A Zemel,Yili Zhang,Samir Gupta,Adil Alaoui,Andrew Ip,Michael B Atkins,Meredith Regan,Neil J Shah

doi:10.1136/jitc-2023-sitc2023.1418

1418 Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan

Jacob Zaemes, Shaked Lev Ari + Show 13 more

Open Access

https://doi.org/10.1136/jitc-2023-sitc2023.1418

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Oct 31, 2023
License type: CC BY-NC 4.0

Affiliation: Hackensack University Medical Center, Dana-Farber Cancer Institute, MedStar Georgetown University Hospital, Georgetown University, Memorial Sloan Kettering Cancer Center

#Treatment-free Survival #Immune Checkpoint Inhibitor Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundPatients (pts) receiving immune checkpoint inhibitor (ICI) therapy can experience periods of prolonged disease control after treatment discontinuation. Previous studies have used treatment-free survival (TFS) to characterize this interval in...

Full Text